Verona Pharma PLC Form 4 insider transactions

Director Lisa Deschamps received 96,000 Restricted Share Units (RSUs) convertible to American Depositary Shares (ADSs) in Verona Pharma plc on April 25, 2025, according to a Form 4 filing.

Director Kenneth Cunningham receives 96,000 Restricted Share Units (RSUs) in Verona Pharma plc, vesting quarterly starting August 1, 2025.

Michael Austwick, a director of Verona Pharma plc, was granted 96,000 Restricted Share Units (RSUs) on April 25, 2025, which vest in installments over the next year.

Director James Aloysius Brady receives 96,000 Restricted Share Units (RSUs) in Verona Pharma plc, vesting quarterly starting August 1, 2025.

Director Christina Ackermann receives an award of 96,000 Restricted Share Units (RSUs) convertible to American Depositary Shares (ADSs) of Verona Pharma plc.

Kathleen A. Rickard, Chief Medical Officer of Verona Pharma plc, sold 79,264 ordinary shares at an average price of $8.3511, executed under a pre-arranged 10b5-1 trading plan.

Director David R. Ebsworth exercised share options and disposed of ordinary shares of Verona Pharma plc on February 26, 2025.

CEO David Zaccardelli reports acquisition and disposal of Verona Pharma shares following the company's first commercial sale of ensifentrine.

Chief Financial Officer of Verona Pharma, Mark Hahn, reports acquisition and disposal of ordinary shares related to vesting of performance restricted share units and tax obligations.

Kathleen A. Rickard, Chief Medical Officer of Verona Pharma, reports acquisition of shares upon vesting of performance restricted share units and disposition of shares to cover tax obligations.

Verona Pharma's CEO, David Zaccardelli, sold a total of 870,672 ordinary shares over three days, as part of a pre-arranged 10b5-1 trading plan.

Verona Pharma's Chief Financial Officer, Mark W. Hahn, sold a total of 881,960 ordinary shares over three days, according to a recent SEC filing.

Verona Pharma's Chief Financial Officer, Mark Hahn, sold a total of 113,240 ordinary shares between November 27 and December 2, 2024, under a pre-arranged 10b5-1 trading plan.

Verona Pharma's CEO, David Zaccardelli, sold a total of 125,328 ordinary shares across three transactions under a pre-arranged 10b5-1 trading plan.

Verona Pharma's Chief Financial Officer, Mark W. Hahn, sold a total of 2,400 ordinary shares through pre-arranged transactions on November 25th and 26th, 2024.

Verona Pharma's CEO, David Zaccardelli, sold 1,600 ordinary shares at $5 each, as part of a pre-arranged trading plan.

Kathleen A. Rickard, Chief Medical Officer of Verona Pharma, sold 240,000 ordinary shares at an average price of $4.9015 per share.

Director David Ebsworth of Verona Pharma plc acquired 20,000 ordinary shares at a price of $4.44 per share on November 18, 2024.

Verona Pharma's CEO, David Zaccardelli, sold 2,400 ordinary shares at $5 each, as part of a pre-arranged trading plan.

Verona Pharma's Chief Financial Officer, Mark W. Hahn, sold 2,400 ordinary shares at $5 per share, according to a recent SEC filing.

Director David Ebsworth recently acquired 39,360 ordinary shares of Verona Pharma plc at a price of $4.7988 per share.

Christina Ackermann, a director at Verona Pharma plc, recently purchased 41,880 ordinary shares represented by 5,235 American Depositary Shares (ADSs) at a price of $4.737 per share.

Verona Pharma's CEO, David Zaccardelli, executed sales of ordinary shares on November 1st and 4th, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Mark Hahn, CFO of Verona Pharma plc, sold a total of 129,672 ordinary shares across two days in November 2024, executed under a pre-arranged Rule 10b5-1 trading plan.

David Zaccardelli, CEO of Verona Pharma, reports acquisition and disposal of ordinary shares, including awards of Restricted Share Units and shares from vesting Performance Restricted Share Units.

Kathleen Rickard, Chief Medical Officer of Verona Pharma, reports acquisition and disposal of ordinary shares, including those related to Restricted Share Units (RSUs) and Performance Restricted Share Units.

Mark Hahn, CFO of Verona Pharma, reports acquisition and disposal of ordinary shares, including awards of Restricted Share Units and shares from vesting Performance Restricted Share Units.

Andrew Fisher, General Counsel of Verona Pharma plc, reports the acquisition of 300,000 ordinary shares through a Restricted Share Unit (RSU) award on October 30, 2024.

Mark Hahn, CFO of Verona Pharma plc, sold a portion of his holdings in ordinary shares through transactions on October 24 and 25, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Verona Pharma's CEO, David Zaccardelli, executed sales of ordinary shares between October 23 and October 25, 2024, under a pre-arranged Rule 10b5-1 trading plan.